Development Modalities | Platform

Development Modalities

Systemic Therapeutics

Publications: Scientific Presentations:

Cell Reports – December 19, 2017
Systemic Messenger RNA Therapy as a Treatment for Methylmalonic Acidemia
Publication | Press Release

No presentations at this time

Prophylactic Vaccines

Publications: Scientific Presentations:

Vaccine – February 20, 2018
Multi-Antigenic Human Cytomegalovirus mRNA Vaccines that Elicit Potent Humoral and Cell-Mediated Immunity
Publication

The Journal of Immunology – November 27, 2017
Rhesus Macaque Myeloid-Derived Suppressor Cells Demonstrate T Cell Inhibitory Functions and Are Transiently Increased after Vaccination
Publication

Frontiers in Immunology – November 13, 2017
Induction of Robust B Cell Responses after Influenza mRNA Vaccination Is Accompanied by Circulating Hemagglutinin-Specific ICOS+ PD-1+ CXCR3+ T Follicular Helper Cells
Publication

Molecular Therapy – August 12, 2017
Efficient Targeting and Activation of Antigen Presenting Cells In Vivo after Modified mRNA Vaccine Administration in Rhesus Macaques
Publication | Press Release | Blog

Cell – July 13, 2017
Vaccine Mediated Protection Against Zika Virus-Induced Congenital Disease
Publication | Press Release
Washington University School of Medicine in St. Louis News Release
National Institute of Allergy and Infection Diseases News Release

New England Journal of Medicine – May 11, 2017
Commentary/Clinical Implications of Basic Research
Zika Virus Vaccines – A Full Field and Looking for the Closer
Article

Molecular Therapy - April 27, 2017
Preclinical and clinical demonstration of immunogenicity by mRNA vaccines against H10N8 and H7N9 influenza viruses
Publication | Press Release | Video & Webcast

Cell - February 17, 2017
Modified mRNA vaccines protect against Zika virus infection
Publication | Press Release

4th International mRNA Health Conference – November 2, 2016
Boston, MA
Moderna mRNA Vaccines: from Concept to Clinic
Presentation

Localized Regenerative Therapeutics

Publications: Scientific Presentations:

Nat Biotech – September 8, 2013
Modified mRNA directs the fate of heart progenitor cells and induces vascular regeneration after myocardial infarction
Publication

Molecular Therapy – June 15, 2018
Biocompatible, Purified VEGF-A mRNA Improves Cardiac Function after Intracardiac Injection 1 Week Post-Myocardial Infarction in Swine
Publication

AHA Scientific Sessions - November 14, 2016
New Orleans, LA
A Biocompatible Chemically Modified mRNA Drives Sustained VEGF-A Protein Production, Human Endothelial Angiogenesis and Epicardial Progenitor Expansion, and Reduces Infarct Size and Partially Reverses Global Cardiac Dysfunction When Intracardially Injected One Week Post-Myocardial Infarction in the Pig
Abstract

4th International mRNA Health Conference – November 1, 2016
Boston, MA
VEGF-A modified mRNA in diabetic wound healing and future treatment opportunities
Presentation

Intratumoral Immuno-Oncology Therapeutics

Publications: Scientific Presentations:

No publications at this time

4th International mRNA Health Conference – November 1, 2016
Boston, MA
Improved outcomes after intratumoral administration of immunostimulatory mRNA in a novel cationic lipid
Presentation

American Association for Cancer Research (AACR) Annual Meeting – April 3, 2017
Washington, DC
Durable efficacy and anti-cancer immunity following intratumoral expression of messenger RNAs encoding IL23, IL36γ and OX40L
Poster

Platform

Publications: Scientific Presentations:

Molecular Therapy – March 14, 2018
A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates
Publication

Nucleic Acids Research – February 23, 2017
N1-methyl-pseudouridine in mRNA enhances translation through eIF2α-dependent and independent mechanisms by increasing ribosome density
Publication

No presentations at this time